Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 4/20 | 0.52 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.52 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.46 |
| ▸ | MIF | P14174 | 2/20 | 0.46 |
| ▸ | CYP24A1 | Q07973 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | STS | P08842 | 1/20 | 0.40 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | GLA | P06280 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALPL | P05186 | 1/20 | 0.39 |
| ▸ | CLK1 | P49759 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7111266 | 0.94 | ESR1 (0.47) | ESR1ESR2MAPTRAB9ANPC1 | |
| SCHEMBL3861662 | 0.92 | ESR1 (0.60) | ESR1ESR2CYP26A1MIFCYP24A1 | |
| SCHEMBL6135986 | 0.90 | ESR1 (0.58) | ESR1ESR2CYP26A1MIFCYP24A1 | |
| SCHEMBL7107472 | 0.87 | ESR1 (0.52) | ESR1ESR2CYP26A1MIFCYP24A1 | |
| SCHEMBL7106199 | 0.86 | ESR1 (0.44) | ESR1ESR2MAPTRAB9ANPC1 | |
| SCHEMBL3976908 | 0.86 | ESR1 (0.55) | ESR1ESR2MIFMAPTRAB9A | |
| SCHEMBL7107480 | 0.86 | ESR1 (0.46) | ESR1ESR2MAPTRAB9ANPC1 | |
| SCHEMBL7106880 | 0.86 | ESR1 (0.51) | ESR1ESR2MAPTRAB9ANPC1 | |
| SCHEMBL7110416 | 0.85 | ESR1 (0.51) | ESR1ESR2MAPTRAB9ANPC1 | |
| SCHEMBL3862097 | 0.85 | ESR1 (0.52) | ESR1ESR2MAPTRAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6599920-B2 | Antiestrogenic compound having fewer or no estrogen agonist properties on reproductive tissues | ELI LILLY AND COMPANY | 2003-07-29 | — | — | US | disclosed |
| US-20030100754-A1 | NAPHTHALENE COMPOUNDS, INTERMEDIATES, FORMULATIONS, AND METHODS | ELI LILLY AND COMPANY | 2003-05-29 | — | — | US | disclosed |
| EP-0826670-B1 | Naphthalene compounds, intermediates, formulations, and methods | LILLY CO ELI (US) | 2002-05-08 | — | — | EP | disclosed |
| EP-0826680-B1 | Dihydronaphthalene and naphthalene compounds, intermediates, formulations, and methods of preparation thereof. | LILLY CO ELI (US) | 2001-10-24 | — | — | EP | disclosed |
| US-6020513-A | BONE DISORDERS | ELI LILLY AND COMPANY (US) | 2000-02-01 | — | — | US | disclosed |
| US-5958916-A | FOR INHIBITING BONE LOSS OR BONE RESORPTION | ELI LILLY AND COMPANY (US) | 1999-09-28 | — | — | US | disclosed |
| EP-0826670-A1 | Naphthalene compounds, intermediates, formulations, and methods | ELI LILLY AND COMPANY (US) | 1998-03-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100754-A1 | NAPHTHALENE COMPOUNDS, INTERMEDIATES, FORMULATIONS, AND METHODS | NDC1, SQLE, NQO1 | ESR1 1044/4885ESR2 2130/4885CYP26A1 208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.